Search results
Results from the WOW.Com Content Network
Ribavirin's amide group can make the native nucleoside drug resemble adenosine or guanosine, depending on its rotation. For this reason, when ribavirin is incorporated into RNA, as a base analog of either adenine or guanine, it pairs equally well with either uracil or cytosine, inducing mutations in RNA-dependent replication in RNA viruses ...
Ribavirin: Hepatitis C [15] nucleoside analogue reverse transcriptase inhibitor: Rilpivirine (Edurant) [16] HIV Rimantadine: Influenza A: M2 proton channel antagonist Ritonavir: HIV HIV-1 protease inhibitor Saquinavir: HIV Simeprevir (Olysio) Hepatitis C Sofosbuvir: Hepatitis C [17] nucleoside analogue reverse transcriptase inhibitor: Stavudine ...
Specifically it is used together with dasabuvir or ribavirin for cases caused by hepatitis C virus genotype 1 or 4. [6] [7] Cure rates are around 95%. [7] It is taken by mouth. [6] It is generally well tolerated. [8] Common side effects include nausea, itchiness, rash, and trouble sleeping. [6]
Gastrointestinal disturbances (including mouth ulcers, indigestion, diarrhea, constipation, etc.) Infections (including sinusitis, the flu, sepsis, UTIs, etc.)
The molecular formula C 8 H 12 N 4 O 5 (molar mass: 244.205 g/mol) may refer to: Azacitidine; Ribavirin, or tribavirin This page was last edited on 6 March 2021, at ...
Prophylactic use of ribavirin and favipiravir in early infection or post-exposure show some efficacy, and both have shown some anti-hantavirus activity in vivo and in vitro. Ribavirin is effective in the early treatment of HFRS with some limitations such as toxicity at high doses and the potential to cause hemolytic anemia. [2]
It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active.
Simeprevir is administered as one capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 or genotype 4 chronic hepatitis C in adult people with compensated liver disease (including cirrhosis), with or without HIV-1 co-infection, who are treatment naive or who have failed previous interferon therapy.